The invention relates to an assay for determining NK-Cell cytotoxicity and the invention particularly relates to a new and improved whole blood flow cytometry based assay. Since in this method, whole blood is used instead of purified cells, the requirement of blood sample volume is significantly reduced and also consumes less time. This assay can be applicable for routine evaluation of NK cell cytotoxicity of patients with various disorders, especially pediatric patients.